PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 16897986-3 2006 S-1 is an oral 5-FU anti-tumor drug that combines three pharmacological agents: tegafur, 5-chloro-2,4-dihydroxypyridine, which inhibits dihydropyrimidine dehydrogenase activity, and potassium oxonate, which reduces gastrointestinal toxicity. gimeracil 89-119 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 16898001-1 2006 S-1 is a newly developed oral anti-tumor agent, which contains 5-chloro-2, 4-dihydroxypyridine and potassium oxonate to strengthen biological activities of 5-fluorouracil. gimeracil 63-94 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 16549996-0 2006 Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1. gimeracil 68-77 proteasome 26S subunit, non-ATPase 1 Homo sapiens 107-110 16897969-2 2006 This novel oral fluoropyrimidine is combined with three pharmacological agents: tegafur (FT) which is a prodrug of 5-fluorouracil (5-FU), 5-chloro-2,4-dihydroxypyridine (CDHP) which inhibits dihydropyrimidine dehydrogenase (DPD) activity, and potassium oxonate (Oxo) which reduces gastrointestinal toxicity. gimeracil 138-168 dihydropyrimidine dehydrogenase Homo sapiens 191-222 16897969-2 2006 This novel oral fluoropyrimidine is combined with three pharmacological agents: tegafur (FT) which is a prodrug of 5-fluorouracil (5-FU), 5-chloro-2,4-dihydroxypyridine (CDHP) which inhibits dihydropyrimidine dehydrogenase (DPD) activity, and potassium oxonate (Oxo) which reduces gastrointestinal toxicity. gimeracil 138-168 dihydropyrimidine dehydrogenase Homo sapiens 224-227 16897967-9 2006 S-1 is an oral anticancer agent in capsule, in which the following 2 modulators for 5-FU are combined to FT: one is CDHP(5-chloro-2,4-dihydroxypyridine) which increases blood concentrations and enhances pharmacological actions of 5-FU by potently inhibiting the degradation of 5-FU; and another is Oxo(potassium oxonate) which is localized in the mucosa of the gastrointestinal (GI) tract after oral administration and reduces GI toxicities provoked by 5-FU. gimeracil 121-151 cadherin 3 Homo sapiens 116-120 15160338-1 2004 BACKGROUND: The goal of the current study was to evaluate the objective response rate and toxicity associated with the oral fluoropyrimidine S-1 (a combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) in patients with previously untreated metastatic colorectal carcinoma. gimeracil 172-202 proteasome 26S subunit, non-ATPase 1 Homo sapiens 141-144 16315929-1 2005 TS-1 is an antitumor drug including 5-chloro-2,4 dihydroxypyridine (CDHP), which inhibits dihydriopyrimidine dehydrogenase (DPD) activity selectively in metabolism of 5-FU. gimeracil 36-66 dihydropyrimidine dehydrogenase Homo sapiens 90-122 16315929-1 2005 TS-1 is an antitumor drug including 5-chloro-2,4 dihydroxypyridine (CDHP), which inhibits dihydriopyrimidine dehydrogenase (DPD) activity selectively in metabolism of 5-FU. gimeracil 36-66 dihydropyrimidine dehydrogenase Homo sapiens 124-127 16315929-1 2005 TS-1 is an antitumor drug including 5-chloro-2,4 dihydroxypyridine (CDHP), which inhibits dihydriopyrimidine dehydrogenase (DPD) activity selectively in metabolism of 5-FU. gimeracil 68-72 dihydropyrimidine dehydrogenase Homo sapiens 90-122 16315929-1 2005 TS-1 is an antitumor drug including 5-chloro-2,4 dihydroxypyridine (CDHP), which inhibits dihydriopyrimidine dehydrogenase (DPD) activity selectively in metabolism of 5-FU. gimeracil 68-72 dihydropyrimidine dehydrogenase Homo sapiens 124-127 15949589-6 2005 Efficacy of 5-chloro-2,4-dihydroxypyridine (CDHP), potent DPD inhibitor, was also examined in 27 cases of them. gimeracil 12-42 dihydropyrimidine dehydrogenase Homo sapiens 58-61 15949589-6 2005 Efficacy of 5-chloro-2,4-dihydroxypyridine (CDHP), potent DPD inhibitor, was also examined in 27 cases of them. gimeracil 44-48 dihydropyrimidine dehydrogenase Homo sapiens 58-61 15949589-8 2005 Six (33.3%) of 18 cases with strong expression of DPD showed 10% or more increment of the anti-tumor effect by adding CDHP to 5-FU. gimeracil 118-122 dihydropyrimidine dehydrogenase Homo sapiens 50-53 15993511-4 2005 Treatment with 5-chloro-2,4-dihydroxypyridine, an inhibitor of DPD, altered the sensitivity to 5-FU in DPD-expressing RERF-LC-MT cells, indicating that modulation of DPD activity could increase the 5-FU sensitivity in lung cancer. gimeracil 15-45 dihydropyrimidine dehydrogenase Homo sapiens 63-66 15993511-4 2005 Treatment with 5-chloro-2,4-dihydroxypyridine, an inhibitor of DPD, altered the sensitivity to 5-FU in DPD-expressing RERF-LC-MT cells, indicating that modulation of DPD activity could increase the 5-FU sensitivity in lung cancer. gimeracil 15-45 dihydropyrimidine dehydrogenase Homo sapiens 103-106 15993511-4 2005 Treatment with 5-chloro-2,4-dihydroxypyridine, an inhibitor of DPD, altered the sensitivity to 5-FU in DPD-expressing RERF-LC-MT cells, indicating that modulation of DPD activity could increase the 5-FU sensitivity in lung cancer. gimeracil 15-45 dihydropyrimidine dehydrogenase Homo sapiens 103-106 15075664-7 2004 This review will focus on the oral fluoropyrimidine S-1, which consists of the 5-FU prodrug tegafur (ftorafur, FT) and two enzyme inhibitors, i.e. CDHP (5-chloro-2,4-dihydroxypyridine) and OXO (potassium oxonate), in a molar ratio of 1(FT):0.4 (CDHP):1(OXO). gimeracil 147-151 proteasome 26S subunit, non-ATPase 1 Homo sapiens 52-55 15075664-7 2004 This review will focus on the oral fluoropyrimidine S-1, which consists of the 5-FU prodrug tegafur (ftorafur, FT) and two enzyme inhibitors, i.e. CDHP (5-chloro-2,4-dihydroxypyridine) and OXO (potassium oxonate), in a molar ratio of 1(FT):0.4 (CDHP):1(OXO). gimeracil 153-183 proteasome 26S subunit, non-ATPase 1 Homo sapiens 52-55 15075664-7 2004 This review will focus on the oral fluoropyrimidine S-1, which consists of the 5-FU prodrug tegafur (ftorafur, FT) and two enzyme inhibitors, i.e. CDHP (5-chloro-2,4-dihydroxypyridine) and OXO (potassium oxonate), in a molar ratio of 1(FT):0.4 (CDHP):1(OXO). gimeracil 245-249 proteasome 26S subunit, non-ATPase 1 Homo sapiens 52-55 15550867-1 2004 BACKGROUND: S-1 is a newly developed novel oral dihydrouracil dehydrogenase inhibiting fluoropyrimidine drug consisting of 1 M tegafur (FT), 0.4 M 5-chloro-2, 4-dihydroxypyrimidine (gimeracil), and 1 M potassium oxonate (oteracil), with efficient antitumor activity and low gastrointestinal toxicity which is widely used in Japan against advanced gastric, head and neck cancers. gimeracil 182-191 proteasome 26S subunit, non-ATPase 1 Homo sapiens 12-15 15331922-1 2004 OBJECTIVE: S-1 is a novel oral fluorouracil antitumor drug that combines three pharmacological agents: tegafur (FT), a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydroxypyridine (CDHP), an inhibitor of dihydropyrimidine dehydrogenase, and potassium oxonate (Oxo), a reducer of gastrointestinal toxicity. gimeracil 153-183 proteasome 26S subunit, non-ATPase 1 Homo sapiens 11-14 15331922-1 2004 OBJECTIVE: S-1 is a novel oral fluorouracil antitumor drug that combines three pharmacological agents: tegafur (FT), a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydroxypyridine (CDHP), an inhibitor of dihydropyrimidine dehydrogenase, and potassium oxonate (Oxo), a reducer of gastrointestinal toxicity. gimeracil 185-189 proteasome 26S subunit, non-ATPase 1 Homo sapiens 11-14 14551502-2 2003 DPD-inhibiting oral fluoropyrimidines showing promise in early clinical studies included UFT (the 5-FU prodrug, tegafur, plus the DPD substrate, uracil), eniluracil (an irreversible DPD inhibitor that improves the oral bioavailability of 5-FU) and S-1 (tegafur plus a reversible DPD inhibitor, 5-chloro-2,4-dihydroxypyridine, and oxonic acid). gimeracil 294-324 dihydropyrimidine dehydrogenase Homo sapiens 0-3 14650374-1 2003 OBJECTIVE: S-1 is an oral anticancer agent combining tegafur (FT), a prodrug of 5-fluorouracil (5-FU), with potassium oxonate (oteracil) and gimeracil (CDHP) respectively to mitigate gastrointestinal toxicity and increase the half-life of 5-FU. gimeracil 141-150 proteasome 26S subunit, non-ATPase 1 Homo sapiens 11-14 12853891-1 2003 TS-1 contains tegaful (FT), 5-chloro-2,4-dihydroxypyridine (CDHP; an inhibitor of 5-fluorouracil (5-FU) degradation) and potassium oxonate (Oxo; an inhibitor of 5-FU assimilation mainly in the digestive tract) in a molar ratio of 1:0.4:1. gimeracil 28-58 Trichinella spiralis resistance 1 Mus musculus 0-4 12044515-0 2002 Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. gimeracil 131-161 dihydropyrimidine dehydrogenase Homo sapiens 78-109 12763215-2 2003 S-1 is a new oral fluorinated pyrimidine derivate, in which the oral 5-fluorouracil (5-FU) prodrug, tegafur, was combined with two 5-FU-modulating substances, 5-chloro-2,4-dihydroxypyridine (gimeracil), and potassium oxonate (oteracil), at a molar ratio of 1:0.4:1. gimeracil 159-189 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 12763215-2 2003 S-1 is a new oral fluorinated pyrimidine derivate, in which the oral 5-fluorouracil (5-FU) prodrug, tegafur, was combined with two 5-FU-modulating substances, 5-chloro-2,4-dihydroxypyridine (gimeracil), and potassium oxonate (oteracil), at a molar ratio of 1:0.4:1. gimeracil 191-200 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 12751387-11 2003 Furthermore, 5-chloro-2,4-dihydroxypyridine (CDHP), a potent DPD inhibitor, enhanced the sensitivity to 5-FU. gimeracil 13-43 dihydropyrimidine dehydrogenase Homo sapiens 61-64 12751387-11 2003 Furthermore, 5-chloro-2,4-dihydroxypyridine (CDHP), a potent DPD inhibitor, enhanced the sensitivity to 5-FU. gimeracil 45-49 dihydropyrimidine dehydrogenase Homo sapiens 61-64 12538461-1 2003 PURPOSE: Our purpose in the study was to determine the maximum tolerated dose and dose-limiting toxicity and investigate the clinical pharmacology of S-1, a combination of tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate. gimeracil 213-217 proteasome 26S subunit, non-ATPase 1 Homo sapiens 150-153 12111108-1 2002 PURPOSE: S-1 is a novel oral fluorouracil antitumor drug that combines tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD), and potassium oxonate (Oxo). gimeracil 85-115 proteasome 26S subunit, non-ATPase 1 Homo sapiens 9-12 12111108-1 2002 PURPOSE: S-1 is a novel oral fluorouracil antitumor drug that combines tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD), and potassium oxonate (Oxo). gimeracil 85-115 cadherin 3 Homo sapiens 117-121 12111108-1 2002 PURPOSE: S-1 is a novel oral fluorouracil antitumor drug that combines tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD), and potassium oxonate (Oxo). gimeracil 85-115 dihydropyrimidine dehydrogenase Homo sapiens 139-170 12111108-1 2002 PURPOSE: S-1 is a novel oral fluorouracil antitumor drug that combines tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD), and potassium oxonate (Oxo). gimeracil 85-115 dihydropyrimidine dehydrogenase Homo sapiens 172-175 12044515-10 2002 These findings suggest that the combination of fluoropyrimidine and CDHP for the treatment of tumours with a high basal DPD elicits a greater antitumour effect than treatment with fluoropyrimidines alone and we suggest that CDHP inhibits the degradation of 5-FU in the tumour. gimeracil 68-72 dihydropyrimidine dehydrogenase Homo sapiens 120-123 12044515-10 2002 These findings suggest that the combination of fluoropyrimidine and CDHP for the treatment of tumours with a high basal DPD elicits a greater antitumour effect than treatment with fluoropyrimidines alone and we suggest that CDHP inhibits the degradation of 5-FU in the tumour. gimeracil 224-228 dihydropyrimidine dehydrogenase Homo sapiens 120-123 12739060-1 2003 S-1 is an oral formulation of ftorafur (FT), oxonic acid and 5-chloro-2,4-dihydroxypyridine (CDHP) at a molar ratio of 1:0.4:1. gimeracil 61-91 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 12739060-1 2003 S-1 is an oral formulation of ftorafur (FT), oxonic acid and 5-chloro-2,4-dihydroxypyridine (CDHP) at a molar ratio of 1:0.4:1. gimeracil 93-97 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 12739060-2 2003 FT is a 5-fluorouracil (5-FU) prodrug, CDHP is a dihydropyrimidine dehydrogenase (DPD) inhibitor and oxonic acid is an inhibitor of 5-FU phosphoribosylation in the gastrointestinal mucosa and was included to prevent gastrointestinal toxicity. gimeracil 39-43 dihydropyrimidine dehydrogenase Homo sapiens 49-80 12739060-2 2003 FT is a 5-fluorouracil (5-FU) prodrug, CDHP is a dihydropyrimidine dehydrogenase (DPD) inhibitor and oxonic acid is an inhibitor of 5-FU phosphoribosylation in the gastrointestinal mucosa and was included to prevent gastrointestinal toxicity. gimeracil 39-43 dihydropyrimidine dehydrogenase Homo sapiens 82-85 12775012-2 2003 S-1 is a novel oral dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine (DIF) based on a biochemical modulation of 5-fluorouracil (5-FU); S-1 contains tegafur (FF) and two types of enzyme inhibitor, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1. gimeracil 213-243 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 12775012-2 2003 S-1 is a novel oral dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine (DIF) based on a biochemical modulation of 5-fluorouracil (5-FU); S-1 contains tegafur (FF) and two types of enzyme inhibitor, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1. gimeracil 213-243 dihydropyrimidine dehydrogenase Homo sapiens 53-56 12775012-2 2003 S-1 is a novel oral dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine (DIF) based on a biochemical modulation of 5-fluorouracil (5-FU); S-1 contains tegafur (FF) and two types of enzyme inhibitor, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1. gimeracil 213-243 tumor necrosis factor Homo sapiens 87-90 12775012-2 2003 S-1 is a novel oral dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine (DIF) based on a biochemical modulation of 5-fluorouracil (5-FU); S-1 contains tegafur (FF) and two types of enzyme inhibitor, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1. gimeracil 245-249 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 12775012-2 2003 S-1 is a novel oral dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine (DIF) based on a biochemical modulation of 5-fluorouracil (5-FU); S-1 contains tegafur (FF) and two types of enzyme inhibitor, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1. gimeracil 245-249 dihydropyrimidine dehydrogenase Homo sapiens 53-56 12775012-2 2003 S-1 is a novel oral dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine (DIF) based on a biochemical modulation of 5-fluorouracil (5-FU); S-1 contains tegafur (FF) and two types of enzyme inhibitor, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1. gimeracil 245-249 tumor necrosis factor Homo sapiens 87-90 12044515-0 2002 Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. gimeracil 131-161 dihydropyrimidine dehydrogenase Homo sapiens 120-123 12044515-0 2002 Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. gimeracil 163-167 dihydropyrimidine dehydrogenase Homo sapiens 78-109 12044515-0 2002 Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. gimeracil 163-167 dihydropyrimidine dehydrogenase Homo sapiens 120-123 12044515-1 2002 The purpose of this study was to evaluate the use of 5-chloro-2,4-dihydroxypyridine (CDHP), a potent inhibitor of dihydropyrimidine dehydrogenase (DPD), to enhance the antitumour activity of the fluoropyrimidines. gimeracil 53-83 dihydropyrimidine dehydrogenase Homo sapiens 114-145 12044515-1 2002 The purpose of this study was to evaluate the use of 5-chloro-2,4-dihydroxypyridine (CDHP), a potent inhibitor of dihydropyrimidine dehydrogenase (DPD), to enhance the antitumour activity of the fluoropyrimidines. gimeracil 53-83 dihydropyrimidine dehydrogenase Homo sapiens 147-150 12044515-1 2002 The purpose of this study was to evaluate the use of 5-chloro-2,4-dihydroxypyridine (CDHP), a potent inhibitor of dihydropyrimidine dehydrogenase (DPD), to enhance the antitumour activity of the fluoropyrimidines. gimeracil 85-89 dihydropyrimidine dehydrogenase Homo sapiens 114-145 12044515-1 2002 The purpose of this study was to evaluate the use of 5-chloro-2,4-dihydroxypyridine (CDHP), a potent inhibitor of dihydropyrimidine dehydrogenase (DPD), to enhance the antitumour activity of the fluoropyrimidines. gimeracil 85-89 dihydropyrimidine dehydrogenase Homo sapiens 147-150 12044515-3 2002 However, CDHP did inhibit 5-fluorouracil (5-FU) degradation and enhanced 5-FU cytotoxicity in a concentration-dependent manner in two human tumour cell lines (MIAPaCa-2 and HuTu80) with relatively high basal DPD activity. gimeracil 9-13 dihydropyrimidine dehydrogenase Homo sapiens 208-211 11290431-12 2001 Furthermore, 5-chloro-2,4-dihydroxypyridine (CDHP), a potent DPD inhibitor, enhanced the sensitivity to 5-FU. gimeracil 13-43 dihydropyrimidine dehydrogenase Homo sapiens 61-64 11497250-1 2001 S-1 is a new oral formulation of 5-fluorouracil (5-FU) containing 1 M tegafur and 0.4 M 5-chloro-2,4-dihydroxypyridine (CDHP) and 1 M potassium oxonate (Oxo). gimeracil 88-118 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 11497250-1 2001 S-1 is a new oral formulation of 5-fluorouracil (5-FU) containing 1 M tegafur and 0.4 M 5-chloro-2,4-dihydroxypyridine (CDHP) and 1 M potassium oxonate (Oxo). gimeracil 120-124 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 11290431-12 2001 Furthermore, 5-chloro-2,4-dihydroxypyridine (CDHP), a potent DPD inhibitor, enhanced the sensitivity to 5-FU. gimeracil 45-49 dihydropyrimidine dehydrogenase Homo sapiens 61-64 10901361-2 2000 This study set out to evaluate, in patients with metastatic colorectal carcinoma, the efficacy and toxicity of S-1, which contains tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, based on a biochemical modulation of 5-fluorouracil (5-FU) targeted at inhibition of dihydropyrimidine dehydrogenase (DPD). gimeracil 140-170 proteasome 26S subunit, non-ATPase 1 Homo sapiens 111-114 10363584-1 1999 S-1 [1 M tegafur (FT)-0.4 M 5-chloro-2,4-dihydroxypyridine (CDHP)-1 M potassium oxonate (Oxo)], was developed as a new oral antineoplastic agent based on biochemical modulation of fluorouracil (5-FU) by CDHP and Oxo. gimeracil 28-58 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 10545788-5 1999 Therefore, to overcome these metabolic events, S-1, an antitumor agent was developed, based on the biochemical modulation of FT by 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo), in a molar ratio of 1:0.4:1. gimeracil 131-161 proteasome 26S subunit, non-ATPase 1 Homo sapiens 47-50 10473078-1 1999 S-1 is a novel oral fluorouracil antitumor drug that combines three pharmacological agents: tegafur (FT), which is a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD) activity; and potassium oxonate (Oxo), which reduces gastrointestinal toxicity. gimeracil 151-181 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 10473078-1 1999 S-1 is a novel oral fluorouracil antitumor drug that combines three pharmacological agents: tegafur (FT), which is a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydroxypyridine (CDHP), which inhibits dihydropyrimidine dehydrogenase (DPD) activity; and potassium oxonate (Oxo), which reduces gastrointestinal toxicity. gimeracil 183-187 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 10363584-1 1999 S-1 [1 M tegafur (FT)-0.4 M 5-chloro-2,4-dihydroxypyridine (CDHP)-1 M potassium oxonate (Oxo)], was developed as a new oral antineoplastic agent based on biochemical modulation of fluorouracil (5-FU) by CDHP and Oxo. gimeracil 60-64 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 10363584-1 1999 S-1 [1 M tegafur (FT)-0.4 M 5-chloro-2,4-dihydroxypyridine (CDHP)-1 M potassium oxonate (Oxo)], was developed as a new oral antineoplastic agent based on biochemical modulation of fluorouracil (5-FU) by CDHP and Oxo. gimeracil 203-207 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 32686977-6 2021 The DPD inhibitor, gimeracil, could block this degradation, which indicated that DPD was the main factor. gimeracil 19-28 dihydropyrimidine dehydrogenase Homo sapiens 4-7 9140762-0 1997 Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry. gimeracil 48-78 proteasome 26S subunit, non-ATPase 1 Homo sapiens 17-20 9140762-1 1997 A high-performance liquid chromatography (HPLC) and gas chromatography-negative ion chemical ionization mass spectrometry (GC-NICI-MS) method was developed for the analysis of the combined antitumor drug S-1 (tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and active metabolite 5-fluorouracil in human plasma and urine. gimeracil 218-248 proteasome 26S subunit, non-ATPase 1 Homo sapiens 204-207 9021668-1 1996 S-1 is a new antineoplastic agent of a fluorinated pyrimidine derivative containing tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1 with the aim of prolonging the effective plasma concentration of 5-fluorouracil (5-FU) and reducing its dose-limiting gastrointestinal toxicity. gimeracil 98-128 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 9021668-1 1996 S-1 is a new antineoplastic agent of a fluorinated pyrimidine derivative containing tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1 with the aim of prolonging the effective plasma concentration of 5-fluorouracil (5-FU) and reducing its dose-limiting gastrointestinal toxicity. gimeracil 130-134 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 33593544-4 2021 Western blot of joint tissues showed that cDHPS significantly inhibited the phosphorylation of IkappaB, p65, JNK, p38, ERK1/2, AKT, PI3K, JAK1 and STAT3 in CIA mice. gimeracil 42-47 v-rel reticuloendotheliosis viral oncogene homolog A (avian) Mus musculus 104-107 33593544-4 2021 Western blot of joint tissues showed that cDHPS significantly inhibited the phosphorylation of IkappaB, p65, JNK, p38, ERK1/2, AKT, PI3K, JAK1 and STAT3 in CIA mice. gimeracil 42-47 mitogen-activated protein kinase 8 Mus musculus 109-112 33593544-4 2021 Western blot of joint tissues showed that cDHPS significantly inhibited the phosphorylation of IkappaB, p65, JNK, p38, ERK1/2, AKT, PI3K, JAK1 and STAT3 in CIA mice. gimeracil 42-47 mitogen-activated protein kinase 14 Mus musculus 114-117 33593544-4 2021 Western blot of joint tissues showed that cDHPS significantly inhibited the phosphorylation of IkappaB, p65, JNK, p38, ERK1/2, AKT, PI3K, JAK1 and STAT3 in CIA mice. gimeracil 42-47 mitogen-activated protein kinase 3 Mus musculus 119-125 33593544-4 2021 Western blot of joint tissues showed that cDHPS significantly inhibited the phosphorylation of IkappaB, p65, JNK, p38, ERK1/2, AKT, PI3K, JAK1 and STAT3 in CIA mice. gimeracil 42-47 thymoma viral proto-oncogene 1 Mus musculus 127-130 33593544-4 2021 Western blot of joint tissues showed that cDHPS significantly inhibited the phosphorylation of IkappaB, p65, JNK, p38, ERK1/2, AKT, PI3K, JAK1 and STAT3 in CIA mice. gimeracil 42-47 Janus kinase 1 Mus musculus 138-142 33593544-4 2021 Western blot of joint tissues showed that cDHPS significantly inhibited the phosphorylation of IkappaB, p65, JNK, p38, ERK1/2, AKT, PI3K, JAK1 and STAT3 in CIA mice. gimeracil 42-47 signal transducer and activator of transcription 3 Mus musculus 147-152 32686977-6 2021 The DPD inhibitor, gimeracil, could block this degradation, which indicated that DPD was the main factor. gimeracil 19-28 dihydropyrimidine dehydrogenase Homo sapiens 81-84 33564297-10 2020 After third-line oral S-1 (tegafur/gimeracil/oteracil) administration, the serum AFP level significantly dropped and the patient achieved long-term disease control without relapse, surviving more than 19 months after disease presentation. gimeracil 35-44 alpha fetoprotein Homo sapiens 81-84 29445512-2 2018 The eye disorder that is most frequently reported in the cancer chemotherapy is associated with the combination of tegafur/gimeracil/potassium oxonate (S-1). gimeracil 123-132 proteasome 26S subunit, non-ATPase 1 Homo sapiens 152-155 31011915-1 2019 BACKGROUND: S-1 is an oral anticancer drug composed of tegafur (FT), which is a prodrug of 5-FU, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate. gimeracil 97-127 proteasome 26S subunit, non-ATPase 1 Homo sapiens 12-15 31011915-1 2019 BACKGROUND: S-1 is an oral anticancer drug composed of tegafur (FT), which is a prodrug of 5-FU, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate. gimeracil 129-133 proteasome 26S subunit, non-ATPase 1 Homo sapiens 12-15 31011915-4 2019 The aim of this study was to investigate the correlation between tears and plasma concentrations of FT, 5-FU, and CDHP, which are components and active modulator of S-1. gimeracil 114-118 proteasome 26S subunit, non-ATPase 1 Homo sapiens 165-168 32793829-1 2020 S-1 is an anticancer agent that is comprised of tegafur, gimeracil, and oteracil potassium, and is widely used in various carcinomas including oral squamous cell carcinoma (OSCC). gimeracil 57-66 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 30524750-1 2018 Background: S-1 (a combination of tegafur, gimeracil, and oteracil) is used to treat various cancers. gimeracil 43-52 proteasome 26S subunit, non-ATPase 1 Homo sapiens 12-15 29580411-4 2018 ELISA determination revealed that cDHP can inhibit CS-induced enhancement in TNF-alpha and IL-1beta secretion in serum and lung. gimeracil 34-38 tumor necrosis factor Mus musculus 77-86 29580411-4 2018 ELISA determination revealed that cDHP can inhibit CS-induced enhancement in TNF-alpha and IL-1beta secretion in serum and lung. gimeracil 34-38 interleukin 1 beta Mus musculus 91-99 28698442-1 2017 S-1 is an oral antineoplastic agent containing tegafur, gimeracil, and oteracil potassium. gimeracil 56-65 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 28927087-1 2017 Gimeracil or 5-chloro-2,4-dihydroxypyridine (CDHP) enhances the antitumor effects of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase (DPD), which is involved in the degradation of 5-FU. gimeracil 13-43 dihydropyrimidine dehydrogenase Homo sapiens 121-152 28927087-1 2017 Gimeracil or 5-chloro-2,4-dihydroxypyridine (CDHP) enhances the antitumor effects of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase (DPD), which is involved in the degradation of 5-FU. gimeracil 13-43 dihydropyrimidine dehydrogenase Homo sapiens 154-157 28927087-1 2017 Gimeracil or 5-chloro-2,4-dihydroxypyridine (CDHP) enhances the antitumor effects of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase (DPD), which is involved in the degradation of 5-FU. gimeracil 45-49 dihydropyrimidine dehydrogenase Homo sapiens 121-152 28927087-1 2017 Gimeracil or 5-chloro-2,4-dihydroxypyridine (CDHP) enhances the antitumor effects of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase (DPD), which is involved in the degradation of 5-FU. gimeracil 45-49 dihydropyrimidine dehydrogenase Homo sapiens 154-157 28927087-6 2017 The expression levels of DNA double strand break repair proteins, including Ku70, DNA-dependent-protein kinase catalytic subunit (DNA-PKcs), Rad50 and Rad51 in CDHP and/or CDDP-treated cells were detected using western blotting. gimeracil 160-164 protein kinase, DNA-activated, catalytic subunit Homo sapiens 130-138 28927087-6 2017 The expression levels of DNA double strand break repair proteins, including Ku70, DNA-dependent-protein kinase catalytic subunit (DNA-PKcs), Rad50 and Rad51 in CDHP and/or CDDP-treated cells were detected using western blotting. gimeracil 160-164 RAD50 double strand break repair protein Homo sapiens 141-146 28927087-6 2017 The expression levels of DNA double strand break repair proteins, including Ku70, DNA-dependent-protein kinase catalytic subunit (DNA-PKcs), Rad50 and Rad51 in CDHP and/or CDDP-treated cells were detected using western blotting. gimeracil 160-164 RAD51 recombinase Homo sapiens 151-156 28927087-9 2017 Western blotting demonstrated that the expression levels of Ku70, DNA-PKcs, Rad50 and Rad51 were downregulated in cells treated with CDHP and CDDP combination treatment. gimeracil 133-137 X-ray repair cross complementing 6 Homo sapiens 60-64 28927087-9 2017 Western blotting demonstrated that the expression levels of Ku70, DNA-PKcs, Rad50 and Rad51 were downregulated in cells treated with CDHP and CDDP combination treatment. gimeracil 133-137 protein kinase, DNA-activated, catalytic subunit Homo sapiens 66-74 28927087-9 2017 Western blotting demonstrated that the expression levels of Ku70, DNA-PKcs, Rad50 and Rad51 were downregulated in cells treated with CDHP and CDDP combination treatment. gimeracil 133-137 RAD50 double strand break repair protein Homo sapiens 76-81 28927087-9 2017 Western blotting demonstrated that the expression levels of Ku70, DNA-PKcs, Rad50 and Rad51 were downregulated in cells treated with CDHP and CDDP combination treatment. gimeracil 133-137 RAD51 recombinase Homo sapiens 86-91 29191594-1 2017 INTRODUCTION: S-1 is an oral fluoropyrimidine-based combination of tegafur, gimeracil, and oteracil potassium. gimeracil 76-85 proteasome 26S subunit, non-ATPase 1 Homo sapiens 14-17 28927087-1 2017 Gimeracil or 5-chloro-2,4-dihydroxypyridine (CDHP) enhances the antitumor effects of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase (DPD), which is involved in the degradation of 5-FU. gimeracil 0-9 dihydropyrimidine dehydrogenase Homo sapiens 121-152 28927087-1 2017 Gimeracil or 5-chloro-2,4-dihydroxypyridine (CDHP) enhances the antitumor effects of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase (DPD), which is involved in the degradation of 5-FU. gimeracil 0-9 dihydropyrimidine dehydrogenase Homo sapiens 154-157 25169655-8 2015 The DPD inhibitor, 5-chloro-2, 4-dihydroxypyridine (CDHP) significantly enhanced 5-FU-induced apoptosis of CD44(high)/ESA(low) cells. gimeracil 19-50 dihydropyrimidine dehydrogenase Homo sapiens 4-7 27966431-1 2017 INTRODUCTION: The use of adjuvant chemotherapy with S-1 (tegafur, gimeracil, and oteracil potassium) has been shown to improve the outcome of patients with gastric cancer. gimeracil 66-75 proteasome 26S subunit, non-ATPase 1 Homo sapiens 52-55 27643822-3 2017 S-1 (Teysuno ), an oral formulation containing the 5-fluorouracil (5-FU) prodrug tegafur and the two enzyme modulators gimeracil and oteracil, has not been available in non-Asia countries until recently. gimeracil 119-128 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 27980246-1 2017 S-1 is a new oral fluoropyrimidine formulation that comprises tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate. gimeracil 71-101 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 25810324-1 2015 S-1 is an oral 5-fluorouracil agent containing tegafur, 5-chloro-2, 4-dihydroxypyridine (CDHP), and potassium oxonate. gimeracil 56-87 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 25810324-1 2015 S-1 is an oral 5-fluorouracil agent containing tegafur, 5-chloro-2, 4-dihydroxypyridine (CDHP), and potassium oxonate. gimeracil 89-93 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 26396918-6 2015 Conversely, gimeracil, a DPD inhibitor, markedly increased the intracellular 5-FU concentration, decreased the intracellular FUPA concentration, and attenuated 5-FU resistance of TE-5R cells. gimeracil 12-21 dihydropyrimidine dehydrogenase Homo sapiens 25-28 28159957-1 2017 Background: S-1 is a combination of tegafur [metabolized to 5-fluorouracil (5-FU)] with the modulators gimeracil (5-chloro-2,4-dihydroxypyridine) and oteracil potassium. gimeracil 103-112 proteasome 26S subunit, non-ATPase 1 Homo sapiens 12-15 28159957-1 2017 Background: S-1 is a combination of tegafur [metabolized to 5-fluorouracil (5-FU)] with the modulators gimeracil (5-chloro-2,4-dihydroxypyridine) and oteracil potassium. gimeracil 114-144 proteasome 26S subunit, non-ATPase 1 Homo sapiens 12-15 28496035-1 2017 S-1 is an anticancer agent that consists of tegafur, gimeracil, and oteracil potassium at a molar ratio of 1:0.4:1. gimeracil 53-62 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 25169655-8 2015 The DPD inhibitor, 5-chloro-2, 4-dihydroxypyridine (CDHP) significantly enhanced 5-FU-induced apoptosis of CD44(high)/ESA(low) cells. gimeracil 19-50 cadherin 3 Homo sapiens 52-56 25169655-8 2015 The DPD inhibitor, 5-chloro-2, 4-dihydroxypyridine (CDHP) significantly enhanced 5-FU-induced apoptosis of CD44(high)/ESA(low) cells. gimeracil 19-50 CD44 molecule (Indian blood group) Homo sapiens 107-111 25550798-15 2014 Celecoxib and celecoxib in combination with tegafur/gimeracil/oteracil potassium possibly by reducing the expression of COX-2, in turn down-regulating the expression of VEGF-C, resulted in the inhibition of lymphangiogenesis. gimeracil 52-61 prostaglandin-endoperoxide synthase 2 Mus musculus 120-125 25360167-10 2014 Due to the results obtained in the current study, we hypothesize that CDHP enhanced the antitumor efficacy of 5-FU by inhibiting the excess DPD protein produced by the tumor. gimeracil 70-74 dihydropyrimidine dehydrogenase Homo sapiens 140-143 25550798-15 2014 Celecoxib and celecoxib in combination with tegafur/gimeracil/oteracil potassium possibly by reducing the expression of COX-2, in turn down-regulating the expression of VEGF-C, resulted in the inhibition of lymphangiogenesis. gimeracil 52-61 vascular endothelial growth factor C Mus musculus 169-175 25109221-1 2014 INTRODUCTION: S-1 is an oral fluoropyrimidine derivative, including three pharmacological compounds: tegafur, gimeracil and oteracil, in a molar ratio of 1: 0.4: 1. gimeracil 110-119 proteasome 26S subunit, non-ATPase 1 Homo sapiens 14-17 21675835-8 2011 One oral fluoropyrimidine, S-1, is novel as it combines tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate. gimeracil 65-95 proteasome 26S subunit, non-ATPase 1 Homo sapiens 27-30 25032886-1 2014 INTRODUCTION: S-1 is an oral fluoropyrimidine that consists of tegafur, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate. gimeracil 72-103 proteasome 26S subunit, non-ATPase 1 Homo sapiens 14-17 23719766-1 2013 S-1 (Teysuno( )) is an oral anticancer agent comprising the 5-fluorouracil (5-FU) prodrug tegafur and targeted modulators, gimeracil and oteracil. gimeracil 123-132 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 22860709-2 2012 S-1 , a fourth-generation oral fluoropyrimidine that combines tegafur and two biochemical modulators: gimeracil and oteracil potassium, is now attracting considerable interest. gimeracil 102-111 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 22241359-1 2012 The S-1(tegafur/gimeracil/oteracil potassium)granule was developed to meet the needs of patients with cancer. gimeracil 16-25 proteasome 26S subunit, non-ATPase 1 Homo sapiens 4-7 21673602-1 2011 INTRODUCTION: S-1 is a rationally designed oral agent that combines the 5-fluorouracil prodrug tegafur with gimeracil and oteracil, which inhibit 5-fluorouracil degradation by dihydropyrimidine dehydronase and phosphorylation within the gastrointestinal tract, respectively, to increase antineoplastic activity while reducing gastrointestinal toxicity. gimeracil 108-117 proteasome 26S subunit, non-ATPase 1 Homo sapiens 14-17 23313143-7 2013 Gimeracil, a DPD inhibitor, was checked whether it could reverse the reduced bioavailability of 5-FU. gimeracil 0-9 dihydropyrimidine dehydrogenase Mus musculus 13-16 23710321-2 2013 Here, we report a case of advanced metastatic CBD cancer successfully treated by chemotherapy with gemcitabine combined with S-1 (tegafur+gimeracil+oteracil). gimeracil 138-147 proteasome 26S subunit, non-ATPase 1 Homo sapiens 125-128 23420099-7 2013 Gimeracil, a DPYD inhibitor, enhanced the sensitivity of some cells to 5-FU but decreased the sensitivity of all the cells to CDDP. gimeracil 0-9 dihydropyrimidine dehydrogenase Homo sapiens 13-17 22510597-1 2012 Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase (DPYD), partially inhibits homologous recombination (HR) repair and has a radiosensitizing effect as well as enhanced sensitivity to Camptothecin (CPT). gimeracil 0-9 dihydropyrimidine dehydrogenase Homo sapiens 27-58 22510597-1 2012 Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase (DPYD), partially inhibits homologous recombination (HR) repair and has a radiosensitizing effect as well as enhanced sensitivity to Camptothecin (CPT). gimeracil 0-9 dihydropyrimidine dehydrogenase Homo sapiens 60-64 21668582-0 2011 Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination. gimeracil 0-9 dihydropyrimidine dehydrogenase Homo sapiens 27-58 21668582-1 2011 Gimeracil (5-chloro-2, 4-dihydroxypyridine) is an inhibitor of dihydropyrimidine dehydrogenase (DPYD), which degrades pyrimidine including 5-fluorouracil in the blood. gimeracil 0-9 dihydropyrimidine dehydrogenase Homo sapiens 63-94 21668582-1 2011 Gimeracil (5-chloro-2, 4-dihydroxypyridine) is an inhibitor of dihydropyrimidine dehydrogenase (DPYD), which degrades pyrimidine including 5-fluorouracil in the blood. gimeracil 0-9 dihydropyrimidine dehydrogenase Homo sapiens 96-100 21668582-1 2011 Gimeracil (5-chloro-2, 4-dihydroxypyridine) is an inhibitor of dihydropyrimidine dehydrogenase (DPYD), which degrades pyrimidine including 5-fluorouracil in the blood. gimeracil 11-42 dihydropyrimidine dehydrogenase Homo sapiens 63-94 21668582-1 2011 Gimeracil (5-chloro-2, 4-dihydroxypyridine) is an inhibitor of dihydropyrimidine dehydrogenase (DPYD), which degrades pyrimidine including 5-fluorouracil in the blood. gimeracil 11-42 dihydropyrimidine dehydrogenase Homo sapiens 96-100 21668582-6 2011 siRNA for DPYD were transfected to HeLa cells to investigate the target protein for radiosensitization with gimeracil. gimeracil 108-117 dihydropyrimidine dehydrogenase Homo sapiens 10-14 21668582-9 2011 Gimeracil restrained the formation of foci of Rad51 and replication protein A (RPA), whereas it increased the number of foci of Nbs1, Mre11, Rad50, and FancD2. gimeracil 0-9 RAD51 recombinase Homo sapiens 46-51 21668582-9 2011 Gimeracil restrained the formation of foci of Rad51 and replication protein A (RPA), whereas it increased the number of foci of Nbs1, Mre11, Rad50, and FancD2. gimeracil 0-9 nibrin Homo sapiens 128-132 21668582-9 2011 Gimeracil restrained the formation of foci of Rad51 and replication protein A (RPA), whereas it increased the number of foci of Nbs1, Mre11, Rad50, and FancD2. gimeracil 0-9 MRE11 homolog, double strand break repair nuclease Homo sapiens 134-139 21668582-9 2011 Gimeracil restrained the formation of foci of Rad51 and replication protein A (RPA), whereas it increased the number of foci of Nbs1, Mre11, Rad50, and FancD2. gimeracil 0-9 RAD50 double strand break repair protein Homo sapiens 141-146 21668582-9 2011 Gimeracil restrained the formation of foci of Rad51 and replication protein A (RPA), whereas it increased the number of foci of Nbs1, Mre11, Rad50, and FancD2. gimeracil 0-9 FA complementation group D2 Homo sapiens 152-158 21668582-15 2011 It was found that DPYD is the target protein for radiosensitization by gimeracil. gimeracil 71-80 dihydropyrimidine dehydrogenase Homo sapiens 18-22 21668582-16 2011 The inhibitors of DPYD, such as gimeracil, could enhance the efficacy of radiotherapy through partial suppression of HR-mediated DNA repair. gimeracil 32-41 dihydropyrimidine dehydrogenase Homo sapiens 18-22 21378348-1 2011 UNLABELLED: The purpose of this study was to investigate the effect of gimeracil (CDHP), a reversible dihydropyrimidine dehydrogenase (DPD) inhibitor, on the pharmacokinetics of 5-fluorouracil (5-FU) and other related metabolites by comparing the pharmacokinetic (PK) profile of S-1 (tegafur [FT] + CDHP + oteracil potassium [Oxo]) to that of FT alone. gimeracil 71-80 cadherin 3 Homo sapiens 82-86 21487460-2 2011 We describe the case of a 76-year-old male showing transient effectiveness with an oral 5-fluorouracil derivative, S-1 (tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate), for epirubicin, cyclophosphamide and paclitaxel refractory skin metastases from possible occult breast cancer. gimeracil 129-159 proteasome 26S subunit, non-ATPase 1 Homo sapiens 115-118 21378348-1 2011 UNLABELLED: The purpose of this study was to investigate the effect of gimeracil (CDHP), a reversible dihydropyrimidine dehydrogenase (DPD) inhibitor, on the pharmacokinetics of 5-fluorouracil (5-FU) and other related metabolites by comparing the pharmacokinetic (PK) profile of S-1 (tegafur [FT] + CDHP + oteracil potassium [Oxo]) to that of FT alone. gimeracil 71-80 dihydropyrimidine dehydrogenase Homo sapiens 102-133 21378348-1 2011 UNLABELLED: The purpose of this study was to investigate the effect of gimeracil (CDHP), a reversible dihydropyrimidine dehydrogenase (DPD) inhibitor, on the pharmacokinetics of 5-fluorouracil (5-FU) and other related metabolites by comparing the pharmacokinetic (PK) profile of S-1 (tegafur [FT] + CDHP + oteracil potassium [Oxo]) to that of FT alone. gimeracil 71-80 dihydropyrimidine dehydrogenase Homo sapiens 135-138 21378348-1 2011 UNLABELLED: The purpose of this study was to investigate the effect of gimeracil (CDHP), a reversible dihydropyrimidine dehydrogenase (DPD) inhibitor, on the pharmacokinetics of 5-fluorouracil (5-FU) and other related metabolites by comparing the pharmacokinetic (PK) profile of S-1 (tegafur [FT] + CDHP + oteracil potassium [Oxo]) to that of FT alone. gimeracil 71-80 proteasome 26S subunit, non-ATPase 1 Homo sapiens 279-282 21378348-1 2011 UNLABELLED: The purpose of this study was to investigate the effect of gimeracil (CDHP), a reversible dihydropyrimidine dehydrogenase (DPD) inhibitor, on the pharmacokinetics of 5-fluorouracil (5-FU) and other related metabolites by comparing the pharmacokinetic (PK) profile of S-1 (tegafur [FT] + CDHP + oteracil potassium [Oxo]) to that of FT alone. gimeracil 71-80 cadherin 3 Homo sapiens 299-303 21963999-1 2011 The product Teysuno (S-1) contains tegafur, a prodrug of 5-fluorouracil (5-FU), and two modulators of 5-FU metabolism, gimeracil and oteracil. gimeracil 120-129 proteasome 26S subunit, non-ATPase 1 Homo sapiens 22-25 21968463-1 2011 BACKGROUND: S-1 is a novel oral agent combining the 5-fluorouracil (FU) prodrug tegafur with gimeracil and oteracil, which inhibit 5-FU degradation by dihydropyrimidine dehydrogenase and phosphorylation within the gastrointestinal tract, respectively. gimeracil 93-102 proteasome 26S subunit, non-ATPase 1 Homo sapiens 12-15 22162925-1 2011 S-1 is a combination of three pharmacological compounds, namely tegafur, gimeracil, and oteracil potassium. gimeracil 73-82 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 18309485-3 2008 S-1 is a novel oral fluoropyrimidine derivative consisting of Tegafur (FT) and dihydropyrimidine dehydrogenase (DPD) inhibitor (5-chloro-2,4-dihydroxypyridine; CDHP). gimeracil 128-158 dihydropyrimidine dehydrogenase Homo sapiens 79-110 19921195-1 2010 PURPOSE: S-1 is an oral anticancer drug containing tegafur (FT), a pro-drug of fluorouracil, combined with two modulators, 5-chloro-2,4-dihydroxypyridine and potassium oxonate (Oxo), at a molar ratio of 1:0.4:1. gimeracil 123-153 proteasome 26S subunit, non-ATPase 1 Homo sapiens 9-12 19724848-1 2009 S-1, an oral fluorouracil antitumor drug, is composed of three agents: tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate (Oxo). gimeracil 85-115 eukaryotic translation elongation factor 1 alpha 2 Mus musculus 0-3 19724848-10 2009 Western blot analysis revealed that treatment with 5-FU and CDHP suppressed expression of integrins alphav, alpha3, alpha6, beta1, beta3, beta4, beta5, and beta6. gimeracil 60-64 cholinergic receptor, nicotinic, alpha polypeptide 3 Mus musculus 108-136 19724848-10 2009 Western blot analysis revealed that treatment with 5-FU and CDHP suppressed expression of integrins alphav, alpha3, alpha6, beta1, beta3, beta4, beta5, and beta6. gimeracil 60-64 basic helix-loop-helix family, member e23 Mus musculus 138-143 19724848-10 2009 Western blot analysis revealed that treatment with 5-FU and CDHP suppressed expression of integrins alphav, alpha3, alpha6, beta1, beta3, beta4, beta5, and beta6. gimeracil 60-64 integrin beta 5 Mus musculus 145-161 19243284-2 2009 S-1 consists of tegafur, a prodrug of 5-FU combined with two 5-FU biochemical modulators:5-chloro-2,4-dihydroxypyridine (gimeracil or CDHP), a competitive inhibitor of dihydropyrimidine dehydrogenase and oteracil potassium which inhibits phosphorylation of 5-FU in the gastrointestinal tract decreasing serious gastrointestinal toxicities,including nausea, vomiting, stomatitis and diarrhea. gimeracil 121-130 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 19052037-8 2009 Thus, S-1 combines FT, CDHP and Oxo at a molar ratio of 1:0.4:1. gimeracil 23-27 proteasome 26S subunit, non-ATPase 1 Homo sapiens 6-9 20559897-1 2010 BACKGROUND: Irinotecan and S-1, an oral fluoropyrimidine composed of tegafur, gimeracil, and oteracil potassium, have demonstrated antitumor activity against advanced gastric cancer. gimeracil 78-87 proteasome 26S subunit, non-ATPase 1 Homo sapiens 27-30 22966328-3 2010 An oral combined fluoropyrimidine drug, S-1 (tegafur, gimeracil and oteracil), has recently been introduced alone or in combination with gemcitabine for BDC. gimeracil 54-63 proteasome 26S subunit, non-ATPase 1 Homo sapiens 40-43 19822965-1 2009 We developed a rapid, simple and sensitive LC/MS/MS method for the simultaneous quantitation of tegafur (FT) and gimeracil (CDHP) in human plasma with a concentration range of 20-5000 and 2-500 ng/mL, respectively. gimeracil 113-122 cadherin 3 Homo sapiens 124-128 19632949-1 2009 S-1 (also known as TS-1; Taiho Pharmaceutical Co. Ltd.; Tokyo, Japan) is a new oral fluoropyrimidine formulation that combines tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate in a molar ratio of 1:0.4:1. gimeracil 136-166 proteasome 26S subunit, non-ATPase 1 Homo sapiens 0-3 25949315-2 2009 The plasma concentration of 5-fluorouracil (5-FU) is increased in patients with renal dysfunction because gimeracil in S-1 inhibits the degradation of 5-FU and about 50% of gimeracil is excreted in the urine. gimeracil 106-115 proteasome 26S subunit, non-ATPase 1 Homo sapiens 119-122 25949315-2 2009 The plasma concentration of 5-fluorouracil (5-FU) is increased in patients with renal dysfunction because gimeracil in S-1 inhibits the degradation of 5-FU and about 50% of gimeracil is excreted in the urine. gimeracil 173-182 proteasome 26S subunit, non-ATPase 1 Homo sapiens 119-122 18309485-3 2008 S-1 is a novel oral fluoropyrimidine derivative consisting of Tegafur (FT) and dihydropyrimidine dehydrogenase (DPD) inhibitor (5-chloro-2,4-dihydroxypyridine; CDHP). gimeracil 128-158 dihydropyrimidine dehydrogenase Homo sapiens 112-115 18172246-5 2008 Interestingly, addition of a dihydropyrimidine dehydrogenase (DPD) inhibitor, such as uracil, 5-chloro-2,4-dihydroxypyridine, or eniluracil, to the fluoropyrimidine treatment regimen significantly diminishes the incidence of HFS. gimeracil 94-124 dihydropyrimidine dehydrogenase Homo sapiens 29-60 19093184-8 2008 S-1 is a prodrug of 5-fluorouracil (5-FU), and contains 5-chloro-2-4-dihydroxypyridine (CDHP), an inhibitor of dihydropyrimidine dehydrogenase (DPD) that rapidly degrades 5-FU. gimeracil 56-86 dihydropyrimidine dehydrogenase Homo sapiens 111-142 19093184-8 2008 S-1 is a prodrug of 5-fluorouracil (5-FU), and contains 5-chloro-2-4-dihydroxypyridine (CDHP), an inhibitor of dihydropyrimidine dehydrogenase (DPD) that rapidly degrades 5-FU. gimeracil 56-86 dihydropyrimidine dehydrogenase Homo sapiens 144-147 18799915-5 2008 Clinicians need to be alert especially to renal dysfunction that induces severe myelosuppression during chemotherapy with S-1, which contains 5-chloro-2,4-dihydroxypyridine (CDHP), a renal excretory inhibitor of dihydropyrimidine dehydrogenase (DPD). gimeracil 142-172 proteasome 26S subunit, non-ATPase 1 Homo sapiens 122-125 18799915-5 2008 Clinicians need to be alert especially to renal dysfunction that induces severe myelosuppression during chemotherapy with S-1, which contains 5-chloro-2,4-dihydroxypyridine (CDHP), a renal excretory inhibitor of dihydropyrimidine dehydrogenase (DPD). gimeracil 142-172 dihydropyrimidine dehydrogenase Homo sapiens 212-243 18799915-5 2008 Clinicians need to be alert especially to renal dysfunction that induces severe myelosuppression during chemotherapy with S-1, which contains 5-chloro-2,4-dihydroxypyridine (CDHP), a renal excretory inhibitor of dihydropyrimidine dehydrogenase (DPD). gimeracil 142-172 dihydropyrimidine dehydrogenase Homo sapiens 245-248 18172246-5 2008 Interestingly, addition of a dihydropyrimidine dehydrogenase (DPD) inhibitor, such as uracil, 5-chloro-2,4-dihydroxypyridine, or eniluracil, to the fluoropyrimidine treatment regimen significantly diminishes the incidence of HFS. gimeracil 94-124 dihydropyrimidine dehydrogenase Homo sapiens 62-65 17982671-7 2007 CDHP (5-chloro-2,4-dihydroxypyridine), an inhibitor of DPD, had an enhancing effect on the apoptotic ability of 5-FU alone or 5-FU/Zeb combination. gimeracil 0-4 dihydropyrimidine dehydrogenase Homo sapiens 55-58 17982671-7 2007 CDHP (5-chloro-2,4-dihydroxypyridine), an inhibitor of DPD, had an enhancing effect on the apoptotic ability of 5-FU alone or 5-FU/Zeb combination. gimeracil 6-36 dihydropyrimidine dehydrogenase Homo sapiens 55-58 17699726-7 2007 Coadministration of a selective DPD inhibitor, 5-chloro-2,4-dihydroxypyridine (CDHP), enhanced the antiproliferative effect of 5-FU and IFN-alpha on KYN-3 approximately 4-fold. gimeracil 47-77 dihydropyrimidine dehydrogenase Homo sapiens 32-35 17708166-2 2007 CFOs should ensure that increased cost exposure in CDHPs is paired with broad, deep disease management and employee assistance support. gimeracil 51-56 Fos proto-oncogene, AP-1 transcription factor subunit Homo sapiens 0-4 17699726-10 2007 Inhibition of DPD activity by CDHP may enhance the efficacy of IFN-alpha and 5-FU combination therapy in patients with HCC showing resistance to this therapy. gimeracil 30-34 dihydropyrimidine dehydrogenase Homo sapiens 14-17 17940834-11 2007 In NUGC-3/5FU/L, 5-FU-enhanced expression of TS mRNA was inhibited by the addition of CDHP. gimeracil 86-90 thymidylate synthetase Homo sapiens 45-47 17699726-7 2007 Coadministration of a selective DPD inhibitor, 5-chloro-2,4-dihydroxypyridine (CDHP), enhanced the antiproliferative effect of 5-FU and IFN-alpha on KYN-3 approximately 4-fold. gimeracil 47-77 interferon alpha 1 Homo sapiens 136-145 17699726-10 2007 Inhibition of DPD activity by CDHP may enhance the efficacy of IFN-alpha and 5-FU combination therapy in patients with HCC showing resistance to this therapy. gimeracil 30-34 interferon alpha 1 Homo sapiens 63-72 17699726-7 2007 Coadministration of a selective DPD inhibitor, 5-chloro-2,4-dihydroxypyridine (CDHP), enhanced the antiproliferative effect of 5-FU and IFN-alpha on KYN-3 approximately 4-fold. gimeracil 79-83 dihydropyrimidine dehydrogenase Homo sapiens 32-35 17699726-7 2007 Coadministration of a selective DPD inhibitor, 5-chloro-2,4-dihydroxypyridine (CDHP), enhanced the antiproliferative effect of 5-FU and IFN-alpha on KYN-3 approximately 4-fold. gimeracil 79-83 interferon alpha 1 Homo sapiens 136-145 17092280-1 2007 OBJECTIVE: To measure dihydropyrimidine dehydrogenase (DPD), an enzyme involved in the metabolism of 5-fluorouracil (5-FU), expression in prostate cancer and determine whether 5-chloro-2,4-dihydroxypyridine (CDHP), a potent inhibitor of DPD, enhances the antitumoral activity of 5-FU against prostate cancer. gimeracil 208-212 dihydropyrimidine dehydrogenase Homo sapiens 22-53 17603216-1 2007 BACKGROUND: TS-1 is a combination preparation of tegafur, a prodrug of 5-fluorouracil (5-FU), with gimeracil, a potent inhibitor of dihydropyrimidine dehydrogenase (DPD), which mediates the inactivation of 5-FU. gimeracil 99-108 dihydropyrimidine dehydrogenase Homo sapiens 132-163 17603216-1 2007 BACKGROUND: TS-1 is a combination preparation of tegafur, a prodrug of 5-fluorouracil (5-FU), with gimeracil, a potent inhibitor of dihydropyrimidine dehydrogenase (DPD), which mediates the inactivation of 5-FU. gimeracil 99-108 dihydropyrimidine dehydrogenase Homo sapiens 165-168 17603216-4 2007 METHODS: We developed a model incorporating the inhibition of DPD by gimeracil and uracil, and fitted the model to the observed kinetics of tegafur and 5-FU after the administration of TS-1 and UFT. gimeracil 69-78 dihydropyrimidine dehydrogenase Homo sapiens 62-65 17092280-1 2007 OBJECTIVE: To measure dihydropyrimidine dehydrogenase (DPD), an enzyme involved in the metabolism of 5-fluorouracil (5-FU), expression in prostate cancer and determine whether 5-chloro-2,4-dihydroxypyridine (CDHP), a potent inhibitor of DPD, enhances the antitumoral activity of 5-FU against prostate cancer. gimeracil 208-212 dihydropyrimidine dehydrogenase Homo sapiens 55-58 16317557-7 2006 Interleukin (IL)-2 production by spleen cells stimulated with concanavalin A was significantly lower in the FT + CDHP group than in the S-1 group. gimeracil 113-117 interleukin 2 Rattus norvegicus 0-18